Rogue Funds, an investment management company, released its fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund returned 8.59% net of fees in the quarter. This quarter, the Fund's volatility has increased significantly, and the firm anticipates that it will continue to do so. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2024.

In its fourth quarter 2024 investor letter, Rogue Funds emphasized stocks such as ElectroCore, Inc. (NASDAQ:ECOR). ElectroCore, Inc. (NASDAQ:ECOR) is bioelectronic medicine and wellness company. The one-month return of ElectroCore, Inc. (NASDAQ:ECOR) was 9.50%, and its shares gained 151.95% of their value over the last 52 weeks. On February 14, 2025, ElectroCore, Inc. (NASDAQ:ECOR) stock closed at $17.41 per share with a market capitalization of $115.884 million.

Rogue Funds stated the following regarding ElectroCore, Inc. (NASDAQ:ECOR) in its Q4 2024 investor letter:

"We experienced volatility in the portfolio as a result of a near round trip in ASP Isotopes and significant appreciation in ElectroCore, Inc. (NASDAQ:ECOR) along with declines in some of our other core positions. I am still very excited about this high growth and high margin business. They hit profitability within the next 6 months while growing revenue at a ~50% consistent CAGR and new devices beginning to scale. Their recent acquisition of NURO (if it gets approved) could be extremely accretive to the company. I have released a few pieces on our blog regarding the company (three now I believe). We trimmed slightly from when we took the position, but it is still a 10%+ position (due to its strong outperformance). The main reason for the trim is that the long-term prospects are extremely strong for the company, but the stock price will be fighting against some fairly strong warrant dilution in the short to midterm which could impact upward momentum on the price over the coming year or so. There could also be some delays in scaling into new networks, scaling their new acquisition, and scaling their new indications. I believe 2025 will be a slightly down year for them, but I believe they will have a ton of momentum going into 2026."

A medical professional discussing the prescription-only therapy with a patient.

ElectroCore, Inc. (NASDAQ:ECOR) is not on our list of 30 Most Popular Stocks Among Hedge Funds.  As per our database, 1 hedge fund portfolios held ElectroCore, Inc. (NASDAQ:ECOR) at the end of the third quarter which was 1 in the previous quarter. The third quarter marks ElectroCore, Inc.’s (NASDAQ:ECOR) eighth consecutive quarter of record revenue. For the three months ending September 30, 2024, ElectroCore, Inc.’s (NASDAQ:ECOR) revenue reached $6.6 million, reflecting a 45% increase compared to the previous year. While we acknowledge the potential of ElectroCore, Inc. (NASDAQ:ECOR) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

In another article we discussed ElectroCore, Inc. (NASDAQ:ECOR) and shared Rogue Funds' views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q3 2024 page for more investor letters from hedge funds and other leading investors.

READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.

Disclosure: None. This article is originally published at Insider Monkey.